This is not the most recent version of the article. View current version (6 MAR 2015)

Intervention Protocol

You have free access to this content

Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in patients with unprovoked VTE

  1. Lindsay Robertson1,*,
  2. Roshan Agarwal2,
  3. Su Ern Yeoh3

Editorial Group: Cochrane Peripheral Vascular Diseases Group

Published Online: 19 NOV 2013

DOI: 10.1002/14651858.CD010837


How to Cite

Robertson L, Agarwal R, Yeoh SE. Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in patients with unprovoked VTE (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD010837. DOI: 10.1002/14651858.CD010837.

Author Information

  1. 1

    The Freeman Hospital, Department of Vascular Surgery, Newcastle upon Tyne, UK

  2. 2

    Imperial College London, Department of Oncology, London, UK

  3. 3

    University of Edinburgh, College of Medicine and Veterinary Medicine, Edinburgh, UK

*Lindsay Robertson, Department of Vascular Surgery, The Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, High Heaton, Newcastle upon Tyne, NE7 7DN, UK. lindsay.robertson@nuth.nhs.uk. lindsay.robertson@ed.ac.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 19 NOV 2013

SEARCH

This is not the most recent version of the article. View current version (06 MAR 2015)

References

Additional references

Baron 1998
Bick 1978
  • Bick RL. Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Seminars in Thrombosis and Hemostasis 1978;5(1):1-26.
Blann 2006
Bremnes 2005
Deeks 2011
  • Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Einstein Investigators
  • EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, et al. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine 2010;363(26):2499-510.
Fritsche
  • Fritsche HA, Grossman HB, Lerner SP, Sawczuk I. National Academy of Clinical Biochemistry Guidelines for the use of tumor markers in bladder cancer. NACB: Practice guidelines and recommendations for use of tumor markers in the clinic. Bladder cancer (3H) (available from http://www.aacc.org/SiteCollectionDocuments/NACB/LMPG/tumor/chp3h_bladder.pdf) (accessed 23 May 2013).
Higgins 2011
  • Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Kakkar 1969
  • Kakkar VV, Flanc C, Howe CT, O'Shea M, Flute PT. Treatment of deep vein thrombosis. A trial of heparin, streptokinase, and Arvin. British Medical Journal 1969;1(5647):806-8, 809-10.
Kakkar 2003
Lee 2003a
Lee 2003b
  • Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine 2003;349(2):146-53.
Levitan 1999
  • Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78(5):285-91.
Limdi 2003
Motzer 1996
Muggia 1990
Mundy 1997
NICE 2012a
  • National Institute for Health and Clinical Excellence. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. NICE clinical guideline 144. Issued June 2012. guidance.nice.org.uk/cg144 (accessed 31 October 2013).
NICE 2012b
  • NHS National Institution for Health and Clinical Excellence. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. NICE technology appraisal guidance 261. Issued: July 2012. guidance.nice.org.uk/ta261 (accessed 31 October 2013).
Piccioli 2004
Prandoni 1997
  • Prandoni P, Piccioli A. Venous thromboembolism and cancer: a two-way clinical association. Frontiers in Bioscience 1997;2:e12-21.
RevMan 2012
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Rodrigues 2010
Ruiz 2003
  • Ruiz Y, Caballero P, Caniego JL, Friera A, Olivera MJ, Tagarro D. Prospective comparison of helical CT with angiography in pulmonary embolism: global and selective vascular territory analysis. Interobserver agreement. European Radiology 2003;13(4):823-9.
Sterne 2011
  • Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
Sturgeon 2009
  • Sturgeon CM, Lai LC, Duffy MJ. Serum tumour markers; how to order and interpret them. BMJ 2009;339(b3527):852-8.
Tefferi 2005
White 2005
  • White RH, Chew HK, Zhou H, Parikh-Patel A, Harris D, Harvey D, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Archives of Internal Medicine 2005;165(15):1782-7.